MNMaphoshane Nchabeleng

Maphoshane Nchabeleng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Maphoshane Nchabeleng has a total of 161 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Whole Genome Characterisation of Non-O1/Non-O139 Vibrio cholerae in Wastewater Treatment Plants in the Tshwane District, South Africa

    by Onalenna Ramocha, Selinah Idah Mulaudzi, John Yenga Bolukaoto, Siesta Rashopole, Kholofelo Malemela, Setshaba Taukobong, Maphoshane Nchabeleng, Renee Street, Andrew Munyalo Musyoki

    Non-O1/non-O139 Vibrio cholerae (NOVC) isolates are non-toxigenic and regarded as etiological agents of infrequent but mild-to-severe human gastroenteritis. In response to the 2022–2023 cholera outbreak in Tshwane, this study investigated the occurrence of NOVC isolates in wastewater within the Tshwane district, South Africa. A total of 341 wastewater samples were screened using Thiosulfate citrate bile salts sucrose (TCBS) media, with subsequent confirmation of Vibrio cholerae (V. cholerae) isolates by multiplex-PCR assays. Rep-PCR was performed to determine the genetic relatedness of the isolates. Selected isolates were subjected to whole genome sequencing (WGS). Of the 341 samples, PCR confirmed 143 isolates as NOVC. Genetic fingerprinting grouped these isolates into 12 distinct clusters, from which 12 representative isolates were selected for WGS and 10 isolates were confirmed as NOVC. The isolates harboured pathogenicity-related genes, such as hlyA and rtxA, as well as other genes contributing to bacterial adaptation such as trkH and tnaA. Drug resistance was mostly observed to first-line antibiotics, ciprofloxacin, chloramphenicol, and trimethoprim–sulfamethoxazole. Plasmid analysis showed six isolates harboured plasmids (pA, p21L, and PVN84) bearing multiple resistance determinants. Phylogenetic analysis showed evidence of genetic diversity amongst isolates. Although the isolates lacked classical toxigenic genes, they carried other virulence determinants associated with pathogenicity, posing a potential risk for clinical infection, highlighting the need for sustained surveillance.

  • Open Access

    Whole Genome Characterisation of Non-O1/Non-O139 Vibrio cholerae Circulating in Wastewater Treatment Plants in the Tshwane District, South Africa

    by Onalenna Ramocha, Selinah Mulaudzi, John Bolukaoto, Siesta Rashopole, Kholofelo Malemela, Setshaba Taukobong, Maphoshane Nchabeleng, Renee Street, Andrew Musyoki

    Non-O1/non-O139 Vibrio cholerae (NOVC) species are typically non-toxic and are regarded as etiological agents of infrequent, but mild to severe human gastroenteritis. In response to the 2022-2023 cholera outbreak in Tshwane, this study investigated the occurrence of NOVC isolates in wastewater within the Tshwane district, South Africa. A total of 341 wastewater samples were screened using Thiosulfate citrate bile salts sucrose (TCBS) media, with subsequent confirmation of Vibrio cholerae (V. cholerae) isolates by multiplex-PCR assays. Rep-PCR was performed to determine genetic relatedness of the isolates. Selected isolates were subjected to whole genome sequencing (WGS). Of the 341 samples; PCR confirmed 143 isolates as NOVC. Genetic fingerprinting grouped these isolates into 12 distinct clusters, from which 12 representative isolates were selected for WGS, all of which were confirmed as NOVC. The isolates harboured pathogenicity-related genes, such as hlyA, rtxA, trkH, tnaA, gyrB and gyrA. Drug resistance was mostly observed to first-line antibiotics, ciprofloxacin, chloramphenicol, and trimethoprim-sulfamethoxazole. Plasmid analysis showed seven isolates harboured plasmids (pA, p21L, PVN84) bearing multiple resistance determinants. Phylogenetic analysis showed evidence of genetic diversity amongst the isolates. Although the isolates lacked classical toxigenic genes, they carried other virulence determinants associated with pathogenicity, posing a potential risk for clinical infection, highlighting the need for sustained surveillance.

  • Immunogenicity and safety of a group B Streptococcus vaccine (GBS-AlpN) in pregnant women and their infants: a phase 2, multicentre, observer-blind, randomised, placebo-controlled study

    by Paul T Heath, Ntokozo Zuma-Gwala, Rikke Bek Helmig, Elizea Horne, Anette Kjærbye-Thygesen, Mie Korslund Wiinblad Crusell, Maphoshane Nchabeleng, Renate Strehlau, Mohammed R Khalil, Christine E Jones, et al.


  • Open Access

    Distribution of emm types and superantigens among group A Streptococcus isolates recovered from northern Tshwane, South Africa

    by Matete O. Kgasha, Skuvet T. Mashailane, Xongani V. Khosa, John Y. Bolukaoto, Marie C. Le Roux, Maphoshane Nchabeleng

    Background: Group A Streptococcus (GAS) is a human pathogen that causes various diseases ranging from localised infections to toxin- and immune-mediated conditions. Objectives: We aimed to describe the prevalence of GAS pharyngitis in northwestern Tshwane and to characterise GAS isolates from this region. Method: GAS isolates were obtained from throat swabs of patients presenting with symptoms of pharyngitis. Clinical isolates were also collected from the DGM Laboratory. Minimum inhibitory concentrations for penicillin, erythromycin and clindamycin were determined using the E-test method. M-protein (emm) typing and superantigens (SAgs) profiles were determined using conventional PCR and sequencing. Results: Among the 400 throat swabs collected, 33 (8%) tested positive for GAS on culture. Additionally, 72 clinical isolates were obtained. Overall, 105 isolates were available, of which 8 (7.6%) were invasive and 97 (92.4%) were non-invasive. All the isolates were susceptible to the tested antibiotics. Twenty-seven emm types were identified, with emm82 being the most prevalent (15%). The potential vaccine coverage among the isolates was 11%. The SAg profiles identified were K and Q. Conclusion: The prevalence of GAS pharyngitis was 8%. No antimicrobial resistance detected. Emm typing showed significant diversity, with more than half of the isolates not covered by the 30-valent M-protein vaccine. The most prevalent was emm82, with speH and speI SAgs equally prevalent in these isolates. The main SAg profiles identified were K and Q. The diversity of these virulence factors suggests that it would be a challenge to consider them as potential vaccine candidates in this region. Contribution: These epidemiological findings offer significant data on the emm types and SAgs in GAS isolates circulating in the region, which may inform the development of an effective vaccine.

  • Open Access

    Safety, effectiveness and immunogenicity of heterologous mRNA-1273 boost after prime with Ad26.COV2.S among healthcare workers in South Africa: The single-arm, open-label, phase 3 SHERPA study

    by Nigel Garrett, Tarylee Reddy, Nonhlanhla Yende-Zuma, Azwidhwi Takalani, Kubashni Woeber, Annie Bodenstein, Phumeza Jonas, Imke Engelbrecht, Waasila Jassat, Harry Moultrie, et al.

    Limited studies have been conducted on the safety and effectiveness of heterologous COVID-19 vaccine boosting in lower income settings, especially those with high-HIV prevalence., The Sisonke Heterologous mRNA-1273 boost after prime with Ad26.COV2.S (SHERPA) trial evaluated a mRNA-1273 boost after Ad26.COV2.S priming in South Africa. SHERPA was a single-arm, open-label, phase 3 study nested in the Sisonke implementation trial of 500000 healthcare workers (HCWs). Sisonke participants were offered mRNA-1273 boosters between May and November 2022, when Omicron sub-lineages were circulating. Adverse events (AE) were self-reported, and co-primary endpoints (SARS-CoV-2 infections and COVID-19 hospitalizations or deaths) were collected through national databases. We used Cox regression models with booster status as a time-varying covariate to determine the relative vaccine effectiveness (rVE) of the mRNA-1273 booster among SHERPA versus unboosted Sisonke participants. Of 11248 SHERPA participants in the rVE analysis cohort (79.3% female, median age 41), 45.4% had received one and 54.6% two Ad26.COV2.S doses. Self-reported comorbidities included HIV (18.7%), hypertension (12.9%) and diabetes (4.6%). In multivariable analysis including 413161 unboosted Sisonke participants, rVE of the booster was 59% (95%CI 29–76%) against SARS-CoV-2 infection: 77% (95%CI 9–94%) in the one-Ad26.COV2.S dose group and 52% (95%CI 13–73%) in the two-dose group. Severe COVID-19 was identified in 148 unboosted Sisonke participants, and only one SHERPA participant with severe HIV-related immunosuppression. Of 11798 participants in the safety analysis, 228 (1.9%) participants reported 575 reactogenicity events within 7 days of the booster (most commonly injection site pain, malaise, myalgia, swelling, induration and fever). More reactogenicity events were reported among those with prior SARS-CoV-2 infections (adjusted odds ratio [aOR] 2.03, 95%CI 1.59–2.59) and less among people living with HIV (PLWH) (aOR 0.49, 95%CI 0.34–0.69). There were 115 unsolicited adverse events (AEs) within 28 days of vaccination. No related serious AEs were reported. In an immunogenicity sub-study, mRNA-1273 increased binding and neutralizing antibody titres and spike-specific T-cell responses 4 weeks after boosting regardless of the number of prior Ad26.COV2.S doses, or HIV status, and generated Omicron spike-specific cross-reactive responses. mRNA-1273 boosters after one or two Ad26.COV2.S doses were well-tolerated, safe and effective against Omicron SARS-CoV-2 infections among HCWs and PLWH. Trial registration: The SHERPA study is registered in the Pan African Clinical Trials Registry (PACTR): PACTR202310615330649 and the South African National Clinical Trial Registry (SANCTR): DOH-27-052022-5778.


  • Open Access

    Sexually transmitted infections amongst men who have sex with men (MSM) in South Africa

    by Rujeko Mashingaidze, Zoe Moodie, Mary Allen, Linda-Gail Bekker, Doug Grove, Nicole Grunenberg, Yunda Huang, Holly E. Janes, Erica Maxine Lazarus, Mookho Malahleha, et al.

    There is limited data about bacterial STIs in MSM populations in sub-Saharan Africa. Our retrospective analysis used data from the HVTN 702 HIV vaccine clinical trial (October 2016 to July 2021). We evaluated multiple variables. Polymerase chain reaction testing was conducted on urine and rectal samples to detect Neisseria gonorrhoea (NG) and Chlamydia trachomatis (CT) every 6 months. Syphilis serology was conducted at month 0 and thereafter every 12 months. We calculated STI prevalence and the associated 95% confidence intervals until 24 months of follow-up. The trial enrolled 183 participants who identified as male or transgender female, and of homosexual or bisexual orientation. Of these, 173 had STI testing done at month 0, median age was 23 (IQR 20–25) years, with median 20.5 (IQR 17.5–24.8) months follow-up (FU). The clinical trial also enrolled and performed month 0 STI testing on 3389 female participants, median age 23 (IQR 21–27) years, median 24.8 (IQR 18.8–24.8) months FU and 1080 non-MSM males with a median age of 27 (IQR 24–31) years, median 24.8 (IQR 23–24.8) months FU. At month 0, CT prevalence was similar in MSM and females (26.0% vs 23.0%, p = 0.492) but was more prevalent in MSM compared to non-MSM males (26.0% vs 14.3%, p = 0.001). CT was the most prevalent STI among MSM at months 0 and 6 but declined from month 0 to month 6 (26.0% vs 17.1%, p = 0.023). In contrast, NG did not decline in MSM between months 0 and 6 (8.1% vs 7.1%, p = 0.680) nor did syphilis prevalence between months 0 and 12 (5.2% vs 3.8%, p = 0.588). Bacterial STI burden is higher in MSM compared to non-MSM males, and CT is the most prevalent bacterial STI amongst MSM. Preventive STI vaccines, especially against CT, may be helpful to develop.


  • Open Access

    Case-fatality and sequelae following acute bacterial meningitis in South Africa, 2016 through 2020

    by Susan Meiring, Cheryl Cohen, Linda de Gouveia, Mignon du Plessis, Vanessa Quan, Jackie Kleynhans, Colin Menezes, Gary Reubenson, Halima Dawood, Maphoshane Nchabeleng, et al.


  • Open Access

    Correlation Between CT Features of Active Tuberculosis and Residual Metabolic Activity on End-of-Treatment FDG PET/CT in Patients Treated for Pulmonary Tuberculosis

    by Ismaheel O. Lawal, Kgomotso M. G. Mokoala, Matsontso Mathebula, Ingrid Moagi, Gbenga O. Popoola, Nontando Moeketsi, Maphoshane Nchabeleng, Chris Hikuam, Jerrold J. Ellner, Mark Hatherill, et al.

    Patients who complete a standard course of anti-tuberculous treatment (ATT) for pulmonary tuberculosis and are declared cured according to the current standard of care commonly have residual metabolic activity (RMA) in their lungs on fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (FDG PER/CT) imaging. RMA seen in this setting has been shown to be associated with relapse of tuberculosis. The routine clinical use of FDG PET/CT imaging for treatment response assessment in tuberculosis is hindered by cost and availability. CT is a more readily available imaging modality. We sought to determine the association between CT features suggestive of active tuberculosis and RMA on FDG PET/CT obtained in patients who completed a standard course of ATT for pulmonary tuberculosis. We prospectively recruited patients who completed a standard course of ATT and declared cured based on negative sputum culture. All patients had FDG PET/CT within 2 weeks of completing ATT. We determined the presence of RMA on FDG PET images. Among the various lung changes seen on CT, we considered the presence of lung nodule, consolidation, micronodules in tree-in-bud pattern, FDG-avid chest nodes, and pleural effusion as suggestive of active tuberculosis. We determine the association between the presence of RMA on FDG PET and the CT features of active tuberculosis. We include 75 patients with a mean age of 36.09 ± 10.49 years. Forty-one patients (54.67%) had RMA on their FDG PET/CT while 34 patients (45.33%) achieved complete metabolic response to ATT. There was a significant association between four of the five CT features of active disease, p < 0.05 in all cases. Pleural effusion (seen in two patients) was the only CT feature of active disease without a significant association with the presence of RMA. This suggests that CT may be used in lieu of FDG PET/CT for treatment response assessment of pulmonary tuberculosis.


  • Open Access

    Genetic determinants of multi-drug resistance in Acinetobacter baumannii at an academic hospital in Pretoria, South Africa

    by Noel-David Nogbou, Dikwata Thabiso Phofa, Maphoshane Nchabeleng, Andrew Munyalo Musyoki

    Antimicrobial resistance is now globally recognised as the greatest threat to human health. Acinetobacter baumanniis’ ( A. baumannii ) clinical significance has been driven by its ability to obtain and transmit antimicrobial resistance factors. In South Africa, A. baumannii is a leading cause of healthcare associated infections (HAI). In this study, we investigated the genetic determinants of multi-drug resistant A. baumannii (MDRAB) at a teaching hospital in Pretoria, South Africa. One hundred non repetitive isolates of A. baumannii were collected for the study at Dr George Mukhari Tertiary Laboratory (DGMTL). Antimicrobial susceptibility testing was performed using the VITEK2 system (bioMerieux, France). The prevalence of common resistance associated genes and AdeABC efflux pump system associated genes were investigated using conventional PCR. Genetic relatedness of isolates was then determined using rep-PCR. Seventy (70) of 100 isolates collected were confirmed to be multi-drug resistant and were bla OXA51 positive. Phenotypically, the isolates where resistant to almost all tested antibiotics. However, one isolate showed intermediate susceptibility to tigecycline while all were susceptible to colistin. Oxacillinase encoding gene bla OXA-23 was the most detected at 99% and only 1% was positive for bla OXA-40 . The PCR results for metallo-betalactamase (MBL) encoding genes showed that MBL bla VIM was the most frequently detected at 86% and bla SIM-1 at 3% was the least detected. Out of 70 isolates, 56 isolates had the required gene combination for an active efflux pump. The most prevalent clone was clone A at 69% of the isolates. Regarding treatment; colistin and tigecycline are the most effective against strains encountered at DGMTL as all tested carbapenems seem to have lost their effectiveness. The major genotypic determinants for drug resistances are oxacillinases: bla OXA-51 (100%) and bla OXA-23 (99%). The study reports for the first time, bla OXA-40 and bla SIM-1 detection in A. baumannii in South Africa.


  • Open Access

    Risk Factors Associated with Group B Streptococcus Colonization and Their Effect on Pregnancy Outcome

    by Lucia Matsiane Lekala, Rooyen Tinago Mavenyengwa, Sylvester Rogers Moyo, Sogolo Lucky Lebelo, John Yenga Bolukaoto, Martina Onyedi Chukwu, Charles Maropeng Monyama, Maphoshane Nchabeleng, Tshimane Charles Tshepuwane, Sam Monokoane

    Background: Group B Streptococcus (GBS) is an important cause of maternal and neonatal morbidity and mortality in many parts of the world. It has been implicated in adverse pregnancy outcomes. Maternal colonization has been found to be a major risk factor for invasive neonatal GBS disease. The main objective of this study was to identify the risk factors of Group B streptococcus colonization and its effect on pregnancy outcome. Methods: This was a prospective study in which pregnant women attending antenatal clinic (ANC) at Dr George Mukhari Hospital (DGMH) were recruited. These were at least18 years old and were at 16 weeks gestation. Vaginal and rectal swabs were taken at recruitment. Follow up of mothers until six weeks post-delivery and babies until three months of age was done. Results: A total of 340 pregnant women were then investigated for GBS colonization. Out of this number, 164 (48.2%) were GBS positive. The majority of the women (62.1%) were parity 1 and 2. Group B Streptococcus colonization was significant in women who had no matric education and who were unemployed. There was a significantly higher GBS colonization in women with previous history of miscarriages and stillbirths. The proportion of HIV positive, GBS colonized women was significant at 41.5% as compared to HIV negative GBS colonized (34.7%). Eight women (4.9%) presented with premature rupture of membranes (PROM) and the duration ranged from 0.5 to 72 hours. Ten (6.1%) women had preterm deliveries. Three (1.8%) women had wound sepsis post caesarean section and one (0.6%) had endometritis post vaginal delivery. A total of 7 (24.1%) babies were GBS positive. The number of live babies delivered was 167, with 1 case of miscarriage due to severe preeclampsia. There were 2 cases of early neonatal deaths which included 1 case of sepsis whereas the other one had multiple congenital abnormalities. Conclusion: Colonization by GBS in pregnant women at DGMH was high. Maternal risk factors identified were previous history of stillbirths/miscarriages, lack of education and being HIV positive. Overall pregnancy outcome both maternal and foetal was good.